Field Service Manager
About the job
- Ability to travel extensively within the United States, primarily by car, including overnight stays, as required by business needs.
- A bachelor's degree in engineering (Electrical, Electronics, Mechanical, or Fluidics) is preferred, or an associate degree with equivalent experience or equivalent military training and experience.
- At least 5 years of Field Service experience in the medical equipment industry, or at least 10 years without a degree.
- Proven management experience with the ability to lead teams, develop talent, and achieve business objectives.
- Strong leadership and mentoring skills related to managing remote teams and operations.
- Excellent communication and customer service skills.
- Proficiency in Microsoft Office and ERP systems.
- A valid driver's license and a good driving record.
- Willingness to travel extensively within the United States and occasionally to Mexico.
- Must reside within the assigned territory and be positioned to support service operations, including coaching and mentoring the service team, engaging with Sales and key customer contacts, and supporting repairs and escalations as needed.
- Ability to perform physical activities including standing, walking, climbing, stooping, kneeling, and crawling.
- Ability to work with possible exposure to blood-borne pathogens and hazardous materials.
- Ability to routinely lift and/or move up to 75 pounds.
- Ensure Outset Medical Tablo system service-level agreement adherence and deliver an excellent customer experience.
- Ensure Field Service Engineers under the manager’s leadership complete required training and field mentorship to meet or exceed their position key performance indicators, scorecards, and regulatory requirements.
- Conduct at least quarterly field visits with each Field Service Engineer to customers to provide support, coaching, and oversight.
- Objectively assess and improve Field Service Engineer performance.
- Build effective business relationships with Sales and key customer contacts to ensure Outset Medical delivers an exceptional customer experience.
- Create projects and programs to drive continuous improvement and increase workforce knowledge and competence.
- Demonstrate urgency in service delivery and maintain strong communication with customers, patients, and internal teams.
- Use Salesforce and Field Service process knowledge to partner with internal stakeholders to improve processes and business systems.
- Recruit and hire Field Service Engineers, ensure they attend Tablo training and receive required training and mentoring upon returning to their territories, and procure necessary tools and other job items.
- Provide on-demand support to Outset employees and customers, including after-hours phone support and holiday and weekend on-site support as required.
- Manage and maintain company assets required to perform job functions.
- Oversee Field Service organization finances, including budget and forecasting, travel and expense oversight and compliance, hiring and compensation, and asset and inventory management.
- Travel extensively within the United States to build relationships with the service team, Sales, and key customer contacts, support repairs and escalations, and provide additional training for Field Service Engineers or customer biomedical technicians.
- Provide support to Marketing or Sales for seminars, trade shows, and other demonstrations as necessary.
- Perform hands-on field work as required by operational and customer needs; the role is approximately 80% management and up to 20% field work.
- Experience as a Service Manager or Team Lead in a medical device company.
- Ability to interpret electronic and fluidics schematic diagrams and flowcharts.
- Advanced computer skills, including Excel, Word, Outlook, PowerPoint, ERP databases, and technology innovation.
- Ability to advocate for customers.
- Experience with service parts management and inventory procedures.
About the company
Outset Medical provides dialysis solutions by pairing the Tablo system with education and hands-on training for dialysis professionals. Tablo integrates with electronic medical records to streamline dialysis workflows, including charting and billing, and provides real-time treatment updates and alerts. They offer a Vascular Access Program to develop staff skills in cannulation and access management, plus a Bridge Program that helps facilities transition from outsourced dialysis to owning their own service line by supplying Outset nurses for 4–13 weeks. Revenue comes from Tablo sales and the accompanying training and support services, with the goal of improving dialysis care across hospitals, clinics, and home care by combining technology with staffing support.
Company Size
501-1,000
Company Stage
IPO
Headquarters
San Jose, California
Founded
2010
Get referred to Outset Medical
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $31.6 million, up 14% sequentially and 1% year-over-year.
- Non-GAAP gross margin improved to 42.2%, showing pricing and manufacturing leverage.
- Management reiterated $125 million-$130 million 2026 revenue guidance after signing the HCA deal.
What critics are saying
- The March 2026 securities case survived dismissal, keeping TabloCart and demand allegations alive.
- John Brottem exits September 11, 2026 without a named successor, weakening legal continuity.
- Outset still burns cash and remains loss-making; another revenue miss would crush credibility.
What makes Outset Medical unique
- Tablo cleared FDA cybersecurity standards in January 2026, first dialysis system to do so.
- Outset bundles water purification, dialysate production, and treatment monitoring into one platform.
- HCA chose a $40 million Tablo refresh through 2028, validating hospital in-sourcing.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Medical, dental, & vision
Life Insurance/AD&D
FSA & HSA
401k
Parental leave
Pet insurance
Tuition reimbursement
PTO
Company events
Growth & Insights and Company News
6 month growth
0%1 year growth
0%2 year growth
-1%Outset Medical (NASDAQ: OM) General Counsel John Brottem to leave September 11. 31 August 2026 09:19 AM PDT Summarize with AI You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to its research reports, in-depth technical and fundamental research. Learn more Outset Medical's General Counsel John Brottem will depart his role effective September 11, 2026, to pursue other professional opportunities. For investors, the company has provided a defined transition date and said the departure is not connected to any dispute or disagreement with Outset Medical or its management. Key Highlights * John Brottem informed Outset Medical of his departure decision on August 27, 2026. * Outset Medical said the departure is not related to a dispute or disagreement with management. * Brottem's departure from Outset Medical takes effect September 11, 2026. * He is leaving both his general counsel position and his role with the company. Departure Effective Date Brottem's departure from Outset Medical is scheduled to take effect on September 11, 2026. The date applies to both his position as general counsel and his role with the company, making the announcement broader than a change limited to one title. The company's disclosure places the effective date after Brottem's notification on August 27. It does not provide additional timing details beyond the stated September 11 departure date. Notification to Outset Medical Brottem notified Outset Medical of his decision on August 27. That notification established the company's understanding that he intended to leave and identified September 11, 2026, as the effective date. It records the notification date, the planned exit date, and the positions covered by the departure. Reason for the Exit The stated reason for Brottem's departure is his pursuit of other professional opportunities. This explanation frames the decision as a move toward opportunities outside the information provided about Outset Medical. No additional career plans or transition arrangements are included in the company's described disclosure. No Dispute or Disagreement Outset Medical described Brottem's departure as unrelated to any dispute or disagreement involving the company or its management. That statement directly addresses whether the exit was connected to a conflict with the organization or its leadership. Instead, the company's stated characterization separates the departure from those circumstances. Roles Covered by the Departure Brottem is leaving his position as general counsel as well as his role with Outset Medical. The wording indicates that the effective September 11 departure concerns both his legal Leadership position and his broader relationship with the company. It also does not describe how the company plans to handle the functions associated with his departure. Company Report and Signature Renee Gaeta, Outset Medical's chief financial officer, signed the company's report on August 28, 2026. Her signature appears in the company reporting associated with the departure disclosure described in the article. The report follows Brottem's August 27 notification by one day and precedes the September 11 effective date. Beyond identifying Gaeta's role and signature date, the article provides no further information about the report's contents or filing process. Peers Moving on This News * RetinalGenix Technologies Inc (OTC: RTGN) little changed * Neuraxis, Inc. (AMEX: NRXS) little changed * Odysight.ai Inc. (NASDAQ: ODYS) up 1.9% FAQs. Q: when will John Brottem leave Outset Medical? A: John Brottem's departure from Outset Medical, including his general counsel position, will take effect on September 11, 2026. The departure also ends his role with the company. Q: when will Brottem leave Outset Medical? A: Brottem's departure is effective September 11, 2026. The effective date covers both his general counsel position and his role with Outset Medical. Q: why is Brottem leaving Outset Medical? A: Brottem notified Outset Medical that he is pursuing other professional opportunities. Q: Was Brottem's departure related to a dispute? A: No. Outset Medical described the departure as unrelated to any dispute or disagreement involving the company or its management. Download Free Report - Explore 3 Stock Ideas & Industry Insights Unlock 3 stock ideas and key industry insights in its free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice. All investments involve risk - consider independent advice before making any investment decisions. Disclaimer:
Outset Medical (NASDAQ:OM) CFO Renee Gaeta sells 4,543 shares of stock. August 18, 2026 Key points. * CFO Renee Gaeta sold 4,543 Outset Medical shares at an average price of $4.39, generating approximately $19,944. The sale covered tax-withholding obligations, leaving her with 180,840 shares. * Outset Medical shares fell to $4.18, while the company reported a quarterly loss of $0.80 per share, missing estimates, despite revenue of $31.64 million exceeding forecasts. * Analysts have a consensus "Hold" rating and a $10.00 price target, with three Buy ratings, one Hold, and one Sell rating. * Five stocks to consider instead of Outset Medical. Outset Medical, Inc. (NASDAQ:OM - Get Free Report) CFO Renee Gaeta sold 4,543 shares of the company's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $4.39, for a total value of $19,943.77. Following the transaction, the chief financial officer owned 180,840 shares of the company's stock, valued at approximately $793,887.60. The trade was a 2.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Renee Gaeta also recently made the following trade(s): * On Wednesday, June 3rd, Renee Gaeta sold 17,672 shares of Outset Medical stock. The shares were sold at an average price of $4.94, for a total transaction of $87,299.68. Outset Medical stock performance. Shares of NASDAQ OM traded down $0.33 during midday trading on Tuesday, hitting $4.18. 143,860 shares of the company's stock were exchanged, compared to its average volume of 407,222. Outset Medical, Inc. has a twelve month low of $3.00 and a twelve month high of $16.16. The firm has a market cap of $78.57 million, a P/E ratio of -1.02 and a beta of 1.96. The stock's 50 day moving average price is $4.58 and its 200-day moving average price is $4.24. The company has a debt-to-equity ratio of 1.03, a current ratio of 5.19 and a quick ratio of 4.11. Outset Medical (NASDAQ:OM - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.08). Outset Medical had a negative net margin of 63.06% and a negative return on equity of 61.67%. The company had revenue of $31.64 million for the quarter, compared to analyst estimates of $28.97 million. Equities research analysts anticipate that Outset Medical, Inc. will post -3.9 EPS for the current year. Hedge funds weigh in on Outset Medical. Several institutional investors and hedge funds have recently modified their holdings of OM. Los Angeles Capital Management LLC acquired a new position in Outset Medical in the fourth quarter worth approximately $29,000. Legal & General Group Plc acquired a new stake in Outset Medical in the second quarter valued at approximately $34,000. BNP Paribas Financial Markets grew its position in Outset Medical by 7,013.8% in the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company's stock worth $40,000 after acquiring an additional 2,034 shares in the last quarter. Hsbc Holdings PLC bought a new stake in Outset Medical in the fourth quarter worth approximately $46,000. Finally, HRT Financial LP acquired a new position in shares of Outset Medical during the 4th quarter worth $58,000. Analysts set new price targets. OM has been the topic of several research reports. TD Cowen reaffirmed a "buy" rating on shares of Outset Medical in a report on Friday, May 8th. Weiss Ratings upgraded Outset Medical from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, August 7th. Finally, Wall Street Zen raised Outset Medical from a "sell" rating to a "hold" rating in a research report on Saturday. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Outset Medical currently has an average rating of "Hold" and a consensus target price of $10.00. Discover more Stock Screener Tool Options Profit Calculator About Outset Medical. Outset Medical is a medical technology company specializing in innovations for renal care. The company's flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy. Tablo's modular design allows for rapid setup and flexible deployment in hospitals, clinics, long-term care facilities and emergency response scenarios. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Outset Medical, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Outset Medical wasn't on the list. While Outset Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
Outset Medical reported second-quarter 2026 revenue of $31.6 million, up 1% year-over-year and 14% sequentially. The dialysis technology company's non-GAAP gross margin improved to 42.2%, up over 380 basis points from the previous year. The company secured a $40 million refresh agreement with HCA Healthcare extending through 2028, providing enhanced revenue visibility. Product revenue declined 5% year-over-year to $21.9 million, whilst service and other revenue grew 17% to $9.7 million. Outset completed its highest number of new site implementations in several years. One Texas system trained over 100 nurses and supported 956 treatments in the first 60 days. The company ended the quarter with $151 million in cash and reiterated full-year 2026 revenue guidance of $125 million to $130 million. It expects to use less than $40 million in cash for the full year.
Outset Medical, Inc. (NASDAQ: OM) investor alert: possible false statements, over $50 million in insider sales. Classactionlawyers advise Outset Medical, Inc. (NASDAQ: OM) investors that the firm is investigating potential legal claims arising from alleged false statements about FDA clearance requirements for one of the company's key products and demand for its dialysis machines. On March 30, 2026, U.S. District Judge Edward J. Davila ruled that key claims in a securities fraud lawsuit against Outset Medical and its CEO and former CFO will move forward. The lawsuit alleges that between September 2020 and August 2024, the company misled investors by describing TabloCart as a non-medical accessory and later touting customer demand for Tablo dialysis systems, despite knowing that TabloCart required clearance from the U.S. Food and Drug Administration and that demand for Tablo was weakening. These statements allegedly caused Outset Medical's stock to trade at artificially inflated prices. Judge Davila found the complaint sufficiently alleged that defendants acted with scienter, or an intent to deceive, in making these false and misleading statements. During this period, company insiders sold over $50 million in stock. After the full truth came out in August 2024, when the company reported disappointing second quarter 2024 results, the stock price fell 68%. Classactionlawyers is investigating potential wrongdoing by Outset Medical's directors and officers in connection with these allegations. If you own Outset Medical stock and wish to obtain additional information about your legal rights, please fill out the form below.
Outset Medical reported Q1 revenue of $27.9 million, down slightly year-over-year due to capital order timing, but reaffirmed full-year guidance of $125–$130 million with growth expected in Q3 and Q4. Product revenue fell 13% to $18.6 million, whilst consumable sales reached $13.2 million and service revenue rose 10% to $9.3 million. Non-GAAP gross margin improved 620 basis points to 43.8% and non-GAAP net loss narrowed to $15.4 million. The company ended the quarter with $161 million in cash and now expects full-year cash usage below $40 million. Management plans a limited release of its next-generation Tablo dialysis system in Q2 through Q3, followed by a full launch. The system will be the first cleared under the FDA's 2025 cybersecurity requirements.